<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992066</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0034</org_study_id>
    <nct_id>NCT03992066</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease</brief_title>
  <official_title>A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900
      milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or
      epoetin alfa), in hemodialysis participants with anemia associated with chronic kidney
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">May 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under concentration-time curve from time 0 to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under concentration-time curve from time 0 to infinity (AUCinf)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed concentration (Tmax)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (tÂ½)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) or clearance (CL)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vd/F) or volume of distribution (Vd)</measure>
    <time_frame>Vadadustat: Days 1, 2, 8, and 10 (or End of Treatment). Erythropoiesis-stimulating agent: Days 1 and 2</time_frame>
    <description>Vadadustat: Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose. Erythropoiesis-stimulating agent: Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for vadadustat metabolite(s)</measure>
    <time_frame>Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast for vadadustat metabolite(s)</measure>
    <time_frame>Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf for vadadustat metabolite(s)</measure>
    <time_frame>Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for vadadustat metabolite(s)</measure>
    <time_frame>Day 1: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose and prior to dosing. Day 8: predose; 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 10 or End of Treatment: predose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum erythropoietin concentration for the erythropoiesis-stimulating agent treatment group</measure>
    <time_frame>Day 1: predose; 0.25, 1, 2, 3, 4, 5, 8, and 11 hours post dose. Day 2: 24 hours (-2 hours) post Day 1 dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepcidin concentration</measure>
    <time_frame>predose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum erythropoietin concentration</measure>
    <time_frame>predose on Days 1, 6, and 10; post dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron concentration</measure>
    <time_frame>predose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin concentration</measure>
    <time_frame>predose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron-binding capcity</measure>
    <time_frame>predose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>predose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>post dose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte concentration</measure>
    <time_frame>predose on Days 1, 6, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event</measure>
    <time_frame>up to Day 40, plus or minus 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant electrocardiogram findings</measure>
    <time_frame>up to Day 40, plus or minus 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant vital sign values</measure>
    <time_frame>up to Day 40, plus or minus 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant clinical laboratory values</measure>
    <time_frame>up to Day 40, plus or minus 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Anemia Associated With Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Vadadustat 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vadadustat 750 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vadadustat 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoiesis-stimulating agent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vadadustat</intervention_name>
    <description>oral 150 mg tablet</description>
    <arm_group_label>Vadadustat 600 mg</arm_group_label>
    <arm_group_label>Vadadustat 750 mg</arm_group_label>
    <arm_group_label>Vadadustat 900 mg</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>solution intravenous injection</description>
    <arm_group_label>Erythropoiesis-stimulating agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>solution for intravenous injection</description>
    <arm_group_label>Erythropoiesis-stimulating agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female â¥18 years of age at the time of informed consent

          -  Receiving chronic, outpatient in-center hemodialysis three times a week for end-stage
             renal disease for at least 12 weeks prior to Screening

          -  Maintained on intravenous erythropoiesis-stimulating agent (ESA) therapy (mean dose of
             &lt;1.5 micrograms per kilogram per week for darbepoetin alfa, or mean dose of &lt;300 Units
             per kilogram per week for epoetin alfa) for 8 weeks prior to randomization

          -  Two hemoglobin values between 8.5 and 10.5 grams per deciliter, inclusive, measured at
             least 4 days apart within 28 days prior to randomization

          -  Investigator determines the participant is not likely to need rescue therapy (ESA
             administration or red blood cell transfusion) or require interruption or
             discontinuation of study drug within the next 30 days

          -  Serum ferritin â¥100 nanograms per milliliter and transferrin saturation â¥20% within
             the 28-day screening period prior to randomization

          -  Folate and vitamin B12 measurements â¥ lower limit of normal within the 28-day
             screening period prior to randomization

          -  Hemodialysis adequacy (Kt/Vurea) as indicated by single-pool Kt/Vurea â¥1.2 using the
             most recent historical measurement within 12 weeks prior to randomization

          -  Female participants of childbearing potential who are non-lactating, not pregnant as
             confirmed by a negative serum pregnancy test at Screening within 9 days prior to
             dosing on Day 1, and using, and agree to continue using, an acceptable method of
             contraception for at least 4 weeks prior to first dose of study drug until 30 days
             after the last dose of study drug. Acceptable contraceptive use is outlined in the
             protocol.

          -  Female participants of non-childbearing potential who are either surgically sterile
             (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy) or
             post-menopausal (&gt;12 months of spontaneous and continuous amenorrhea in a female &gt;55
             years old, or &gt;12 months of spontaneous and continuous amenorrhea with a follicle
             stimulating hormone [FSH] level &gt;40 International Units per Liter in a female &lt;55
             years old)

          -  Female participants of childbearing potential who agree not to donate ova during the
             study and for at least 30 days after the last dose of study drug

          -  Male participants who have not had a vasectomy must agree to use an acceptable method
             of contraception from time of first dose of study drug until 30 days after the last
             dose of the study drug, and to not donate sperm during the study and for at least 30
             days after the last dose of study drug. Acceptable contraceptive use is outlined in
             the protocol.

          -  Understands the procedures and requirements of the study and provides written informed
             consent and authorization for protected health information disclosure

        Exclusion Criteria:

          -  Treated with any HMG-CoA reductase inhibitor (statin) other than atorvastatin,
             pravastatin, simvastatin, or rosuvastatin within the 28-day screening period prior to
             randomization. Within the 28-day screening period prior to randomization, the maximum
             allowable dose of simvastatin is 20 milligrams (mg) daily, and the maximum allowable
             dose of rosuvastatin is 10 mg daily. These restrictions also apply to the dosing
             period.

          -  Treated with clinically relevant substrates of the breast cancer resistant protein
             (BCRP) transporter (e.g., sulfasalazine, methotrexate, mitoxantrone, imatinib,
             irinotecan, lapatinib, topotecan, tenofovir, glecaprevir, pibrentasir, or sofosbuvir)
             within 30 days prior to randomization

          -  Anemia with a cause other than chronic kidney disease (e.g., sickle cell disease,
             myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma,
             hemolytic anemia, thalassemia, or pure red cell aplasia)

          -  Active bleeding or blood loss within 8 weeks prior to randomization

          -  Red blood cell transfusion within 8 weeks prior to randomization

          -  Anticipated to discontinue hemodialysis or change dialysis modality during the study

          -  History of chronic liver disease (e.g., chronic infectious hepatitis, chronic
             autoimmune liver disease, cirrhosis or fibrosis of the liver)

          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT),
             alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total
             bilirubin &gt;1.5Ã upper limit of normal (ULN) within the 28-day screening period prior
             to randomization. Participants with a history of Gilbert's syndrome may participate in
             the study if they are not jaundiced, have a total bilirubin &lt;3 Ã ULN and AST and ALT
             are not &gt;1.5Ã ULN.

          -  Current uncontrolled hypertension that would contraindicate the use of darbepoetin
             alfa or epoetin alfa as determined by the investigator

          -  Acute coronary syndrome (hospitalization for unstable angina or myocardial
             infarction), surgical or percutaneous intervention for coronary, cerebrovascular, or
             peripheral artery disease (aortic or lower extremity), surgical or percutaneous
             valvular replacement or repair, sustained ventricular tachycardia, hospitalization for
             heart failure (HF) or New York Heart Association Class IV HF, or stroke within 12
             weeks prior to randomization

          -  History of new or recurrent malignancy within 2 years prior to Screening or currently
             receiving treatment or suppressive therapy for cancer. Participants with treated basal
             cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or
             cervical carcinoma in situ may participate on the study.

          -  History of deep vein thrombosis or pulmonary embolism within 12 weeks prior to
             randomization

          -  History of hemosiderosis or hemochromatosis

          -  History of bilateral native nephrectomy

          -  History of functioning organ transplantation other than corneal transplant

          -  Scheduled organ transplant from a living donor or on the kidney transplant wait list
             or expected to receive a transplant during the study

          -  History of a prior hematopoietic stem cell or bone marrow transplant (stem cell
             therapy for knee arthritis is not excluded)

          -  Known hypersensitivity to vadadustat excipients, or to darbepoetin alfa or epoetin
             alfa

          -  Use of an investigational drug within 30 days or 5 half-lives of the investigational
             drug (whichever is longer) prior to randomization

          -  Prior administration of an hypoxia-inducible factor prolyl-hydroxylase, including
             vadadustat

          -  Any other reason, which in the opinion of the investigator, would make the participant
             not suitable for participation in the study

          -  Treated with probenecid within the 28-day Screening Period prior to randomization or
             during the study treatment duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midwest City</city>
        <state>Oklahoma</state>
        <zip>73130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Vadadustat</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Erythropoiesis-stimulating agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

